Cargando…

Correction to: SB8: A Bevacizumab Biosimilar

Detalles Bibliográficos
Autor principal:	Syed, Yahiya Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810612/ https://www.ncbi.nlm.nih.gov/pubmed/33306171 http://dx.doi.org/10.1007/s11523-020-00783-1

Ejemplares similares

SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

Correction to: MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2022)

A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
por: Shin, Donghoon, et al.
Publicado: (2020)

Correction to: Regdanvimab: First Approval
por: Syed, Yahiya Y.
Publicado: (2021)

Correction to: Sparsentan: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)

Correction to: Nonacog Beta Pegol: A Review in Haemophilia B
por: Syed, Yahiya Y.
Publicado: (2018)

Correction to: Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
por: Syed, Yahiya Y.
Publicado: (2021)

Correction to: Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
por: Syed, Yahiya Y.
Publicado: (2021)

Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
por: Syed, Yahiya Y.
Publicado: (2021)

Correction to: Perindopril/Indapamide/Amlodipine in Hypertension: A Profile of Its Use
por: Syed, Yahiya Y.
Publicado: (2022)

Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)

Correction: Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids
por: Syed, Yahiya Y.
Publicado: (2022)

Correction to: Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use
por: Syed, Yahiya Y.
Publicado: (2023)

Correction: Estetrol/Drospirenone: A Review in Oral Contraception
por: Lee, Arnold, et al.
Publicado: (2022)

Correction to: DTaP‑IPV‑HepB‑Hib Vaccine (Hexyon(®)): An Updated Review of its Use in Primary and Booster Vaccination
por: Syed, Yahiya Y.
Publicado: (2019)

Correction to: Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema
por: Fung, Simon, et al.
Publicado: (2022)

Correction to: Pegaspargase: A Review in Acute Lymphoblastic Leukaemia
por: Heo, Young-A., et al.
Publicado: (2019)

Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men
por: Markus, Richard, et al.
Publicado: (2017)

Correction to: GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2018)

Correction to: AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Correction: Preparing for the incoming wave of biosimilars in oncology
Publicado: (2018)

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
por: Ebbers, Hans C., et al.
Publicado: (2020)

Correction to: Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Infammation and Pain Following Ocular Surgery
por: Kang, Connie, et al.
Publicado: (2020)

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar
por: Lee, JongAh Joanne, et al.
Publicado: (2023)

MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2021)

Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts
por: Derikx, Lauranne A A P, et al.
Publicado: (2021)

Correction to: To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars
por: Rezk, Mourad F., et al.
Publicado: (2018)

Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
por: Ingram, Rebecca L., et al.
Publicado: (2023)

Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab)
por: Hong, Juyong, et al.
Publicado: (2016)

Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
por: Paek, Kyungyeol, et al.
Publicado: (2019)

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
por: Hummel, Matthew, et al.
Publicado: (2021)

Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma
por: Kumar, Gunjesh, et al.
Publicado: (2021)

Correction: Inhibitory Activity of Bevacizumab to Differentiation of Retinoblastoma Cells
por: Heo, Jang Won, et al.
Publicado: (2012)

SB4 in the Era of Biosimilars: Clinical Data and Real-World Experience
por: Law, Shing T., et al.
Publicado: (2019)

The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab
por: Goldschmidt, Jerome, et al.
Publicado: (2020)

Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept
por: Cho, Ick Hyun, et al.
Publicado: (2016)

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
por: Cao, Di, et al.
Publicado: (2023)

Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2023)

Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
por: Yanagi, Yasuo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s0jemb0scj8tm9plgedr1orahv